Study Summary
This trial is evaluating the use of a device called the THOR LX2.3 with LED Lollipop for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). This device uses light to help prevent mucositis, a common side effect of alloHCT.
Eligible Conditions
- Mouth Sores
- Intraoral Photobiomodulation Therapy
- Mouth Ulcer
- Allogeneic Bone Marrow Transplant
Treatment Effectiveness
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 20 Days
20 Days
Duration of severe Oral Mucositis
Trial Safety
Trial Design
1 Treatment Group
INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT
1 of 1
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: THOR LX2.3 with LED Lollipop · No Placebo Group · N/A
INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT
Device
Experimental Group · 1 Intervention: THOR LX2.3 with LED Lollipop · Intervention Types: DeviceTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 20 days
Who is running the clinical trial?
Dana-Farber Cancer InstituteLead Sponsor
1,016 Previous Clinical Trials
393,778 Total Patients Enrolled
THOR Photomedicine LtdUNKNOWN
Kentaro Ikeda, DDS, MPHPrincipal InvestigatorBrigham and Women's Hospital
Nathaniel S. Treister, DMD, DMScPrincipal InvestigatorBrigham and Women's Hospital
1 Previous Clinical Trials
40 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You are able to understand the nature and purpose of the study and are willing to sign a written informed consent document.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments